Dr. Bauer on Rovalpituzumab Tesirine in SCLC

Todd Bauer, MD
Published: Monday, Oct 03, 2016



Todd Bauer, MD, associate director, Drug Development, Sarah Cannon Research Institute, discusses the emergence of the novel agent rovalpituzumab tesirine (Rova-T) in the treatment of patients with small cell lung cancer (SCLC) in an interview during the IASLC Chicago Multidisciplinary Symposium in Thoracic Oncology.

SCLC, says Bauer, is one of the few cancers that is lacking in targeted therapies. Rova-T, specifically, targets DLL3, a molecule that is expressed in approximately two-thirds of patients with SCLC, making it an excellent marker in this space.

Currently, there are 3 ongoing studies assessing the efficacy of Rova-T. Beyond these trials, Bauer believes oncologists will soon look at Rova-T in a first-line setting, as well as in combination with immunotherapies such as nivolumab (Opdivo) and ipilimumab (Yervoy).


Todd Bauer, MD, associate director, Drug Development, Sarah Cannon Research Institute, discusses the emergence of the novel agent rovalpituzumab tesirine (Rova-T) in the treatment of patients with small cell lung cancer (SCLC) in an interview during the IASLC Chicago Multidisciplinary Symposium in Thoracic Oncology.

SCLC, says Bauer, is one of the few cancers that is lacking in targeted therapies. Rova-T, specifically, targets DLL3, a molecule that is expressed in approximately two-thirds of patients with SCLC, making it an excellent marker in this space.

Currently, there are 3 ongoing studies assessing the efficacy of Rova-T. Beyond these trials, Bauer believes oncologists will soon look at Rova-T in a first-line setting, as well as in combination with immunotherapies such as nivolumab (Opdivo) and ipilimumab (Yervoy).

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x